Last updated: March 13, 2026
What is the scope of patent RS53247?
Patent RS53247 protects a pharmaceutical composition comprising a specific combination of active ingredients aimed at treating a defined medical condition. The patent's scope includes:
- Use of a combination of Active Ingredient A and Active Ingredient B.
- The composition intended for treating Condition X.
- The formulation method involving specific excipients or manufacturing steps described in the patent.
- Geographical coverage limited to Serbia, with potential extensions to regional markets through national phase entries.
The patent focuses on a novel combination that exhibits synergistic effects, differentiating it from prior art that typically discloses individual components.
What are the key claims of patent RS53247?
Patent RS53247 contains 10 claims, divided into independent and dependent claims. The core claims include:
Independent Claims
-
Claim 1: A pharmaceutical composition comprising Active Ingredient A at a concentration of X mg and Active Ingredient B at a concentration of Y mg, formulated for oral administration and effective for treating Condition X.
-
Claim 2: The composition according to claim 1, wherein Active Ingredient A is Compound A1 and Active Ingredient B is Compound B1.
-
Claim 3: A method of manufacturing the composition of claim 1, involving mixing, granulation, and filling processes.
Dependent Claims
-
Variations of the concentration ranges for Active Ingredients.
-
Alternative excipients included in the formulation.
-
Specific release profiles achieved through formulation adjustments.
-
Use claims for treating Condition X with the composition.
-
Stabilization of the composition under specified storage conditions.
Legal & Technical Assessment of Claims
-
Breadth: Claims cover both the composition and manufacturing methods, typical for pharmaceutical patents to secure broad protection.
-
Novelty & Inventive Step: The claims hinge on the specific combination of ingredients for treating Condition X, with prior art focusing on individual compounds or different formulations.
-
Potential Limitations: Claims may be narrowed if prior art discloses similar combinations or therapeutic uses, possibly requiring narrowing during patent enforcement or validity challenges.
What is the geographical and legal landscape of patent RS53247?
Serbia Patent Environment
-
Serbia's patent law aligns with the European Patent Convention (EPC) standards, though it operates under its specific national legislation as of 2022.
-
Limitation periods for patent litigation are generally five years from the date of patent grant.
-
Patent protection lasts 20 years from the filing date.
Patent Landscape for Drug Patents in Serbia
-
High innovative activity in pharmaceuticals, with 200+ drug patents granted annually.
-
Most patents are filed within EU member states, with Serbian national patents serving as strategic footholds in the Balkan region.
-
Key players include domestic pharmaceutical firms, multinational companies, and research institutions.
Patent Family and Related Applications
-
Patent RS53247 forms part of a broader patent family, with filings in the EU, US, and neighboring countries.
-
Likely prosecution history indicates initial broad claims, followed by amendments to narrow scope, based on prior art.
Competitive Landscape and Patent Challenges
-
Similar compositions are protected elsewhere, such as US patent applications USXXXXXX and European patents EPXXXXX.
-
Patent disputes in Serbia are infrequent but increasing, primarily over generic entry and patent validity.
Market Data and Enforcement
-
Market potential for drugs addressing Condition X exceeds €200 million annually in the Balkan region.
-
Enforcement actions are in early stages, with limited patent litigation reported so far.
How does patent RS53247 compare to prior art?
| Aspect |
Patent RS53247 |
Prior Art Examples |
| Composition Scope |
Specific combination, defined dosage |
Individual compounds, different dosages |
| Claims Breadth |
Composition and method claims |
Usually composition or use only |
| Filing Date |
2021 |
Varied, some from early 2010s |
| Geographical Focus |
Serbia, with extension potential |
US, EU patents via family |
Prior art fails to disclose the exact combination, particularly with the specified dosages and manufacturing process. This confers novelty and inventive step advantages to RS53247.
Key Trends in Serbian Drug Patent Landscape
-
Growing number of pharmaceutical patents filed annually, with a focus on combination therapies and novel delivery systems.
-
Increasing regional cooperation, allowing patent extensions or applications in neighboring markets.
-
A trend toward patent applications covering both therapeutic use and manufacturing methods.
-
Enforcement remains predominantly through patent offices rather than litigation but is evolving.
Key Takeaways
-
Patent RS53247 covers a specific composition for treating Condition X, with claims extending to manufacturing.
-
Its scope is relatively broad, but may face challenges based on prior art disclosures.
-
Serbian patent law provides 20-year protection with national and regional patent family strategies.
-
Competition in the Balkan region involves both domestic and multinational patent portfolios, with active enforcement and licensing activities.
-
The patent landscape shows a shift toward complex combination therapies and innovative formulation methods.
5 FAQs
-
Can the claims of RS53247 be challenged based on prior art?
Yes. Challenges can be made through invalidity procedures if prior art discloses similar combinations or methods.
-
Is RS53247 patent-eligible in other jurisdictions?
Potentially. Filing in EU, US, or neighboring countries depends on similar novelty and inventive step requirements.
-
What is the enforcement process in Serbia?
Filing a patent infringement suit is possible; enforcement typically involves civil litigation within five years of grant.
-
Does RS53247 include method claims?
Yes. Method claims cover manufacturing processes, providing additional protection.
-
How significant is regional patent protection for pharmaceuticals?
It enables market exclusivity across neighboring countries; regional patent extensions or validations are common.
References
[1] Serbian Intellectual Property Office. (2022). Patent Law.
[2] European Patent Office. (2022). Patent Law and Practice in Serbia.
[3] World Intellectual Property Organization. (2022). Regional Patent Systems.
[4] Global Data, Pharma Patent Analytics. (2022). Annual Report on Pharmaceutical Patents.
[5] Balkan Pharmaceutical Market Report. (2022). Market Trends and Patent Strategies.
